(2E)-3-(4-Bromophenyl)-1-[4-(4-methoxybenzoyl)-1-piperazinyl]-2-propen-1-one recently known as NIBR 189, is a selective Epstein-barr virus-induced gene 2 (EBI-2) receptor antagonist, resulting in a modulation of immune responses related to auto-immune diseases.